FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3023173837> ?p ?o ?g. }

• W3023173837 abstract "Abstract Background: Injectable somatostatin receptor ligands (SRLs) are the most widely used therapy to control acromegaly. Oral octreotide capsules have been formulated as a potential therapy for this disorder and the efficacy and safety was evaluated in the CHIASMA OPTIMAL prospective phase 3 study in patients with acromegaly who were controlled on injectable SRL treatment of varying doses (Samson et al. ENDO 2020). Methods: Patients with confirmed acromegaly, who had been receiving a stable dose of injectable SRL (≥3 months) up until study entry, were randomized to receive octreotide capsules (40 mg/day) or placebo for 36 weeks. Patients were dose titrated to 60 or 80 mg of oral octreotide or equivalent placebo through week 24 at the investigator’s discretion based on increase of IGF-I levels or worsening of acromegaly signs and symptoms. The primary efficacy endpoint was the proportion of patients who maintained their biochemical response at the end of 36 weeks, defined as average IGF-I ≤1 x ULN between Weeks 34 and 36. An analysis evaluated maintenance of response based on prior dose of injectable SRL. Prior doses of injectable SRL were categorized based on the following classifications: octreotide 10 mg every 4 weeks or lanreotide 60 mg every 4 weeks or 120 mg every 8 weeks were stratified as low; octreotide 20 mg every 4 weeks or lanreotide 90 mg every 4 weeks or 120 mg every 6 weeks were stratified as medium; octreotide 30 mg or 40 mg or lanreotide 120 mg every 4 weeks were stratified as high. Randomization was stratified based on low dose vs med/high dose and efficacy results compared for these strata. The response rates reported for the primary end point are slightly adjusted for stratification differences as prespecified in the statistical analysis plan. Results: Six patients (21.4%) in the octreotide capsule group had received prior treatment with low doses of injectable SRLs while 22 (78.6%) had received prior treatment with medium-high doses of injectable SRLs. Maintenance of response was observed in 16 patients receiving oral octreotide. This included 66.7% of patients (n=4) previously receiving low doses of injected SRLs and 54.5% of patients (n=12) on medium-high injected doses. The treatment effect was consistent irrespective of prior dose of injectable SRL (odds ratio: 5.4 in low dose and 5.9 in medium-high dose). Conclusion: The CHIASMA OPTIMAL study recruited a population receiving predominantly medium-high doses of injectable SRLs and demonstrated maintenance of response in 58% of patients. Oral octreotide treatment effect was consistent irrespective of prior dose of injectable SRL." @default.
• W3023173837 created "2020-05-13" @default.
• W3023173837 creator A5003838671 @default.
• W3023173837 creator A5007146249 @default.
• W3023173837 creator A5022118831 @default.
• W3023173837 creator A5024070567 @default.
• W3023173837 creator A5033667607 @default.
• W3023173837 creator A5042807722 @default.
• W3023173837 creator A5045002153 @default.
• W3023173837 creator A5048100872 @default.
• W3023173837 creator A5049091175 @default.
• W3023173837 creator A5059278248 @default.
• W3023173837 creator A5066985276 @default.
• W3023173837 creator A5071111551 @default.
• W3023173837 creator A5076785961 @default.
• W3023173837 date "2020-04-01" @default.
• W3023173837 modified "2023-10-01" @default.
• W3023173837 title "MON-LB53 Prior Injectable Somatostatin Receptor Ligand Dose Does Not Predict Oral Octreotide Response In The Treatment Of Acromegaly: Results From The Phase 3 OPTIMAL Study" @default.
• W3023173837 doi "https://doi.org/10.1210/jendso/bvaa046.2121" @default.
• W3023173837 hasPublicationYear "2020" @default.
• W3023173837 type Work @default.
• W3023173837 sameAs 3023173837 @default.
• W3023173837 citedByCount "0" @default.
• W3023173837 crossrefType "journal-article" @default.
• W3023173837 hasAuthorship W3023173837A5003838671 @default.
• W3023173837 hasAuthorship W3023173837A5007146249 @default.
• W3023173837 hasAuthorship W3023173837A5022118831 @default.
• W3023173837 hasAuthorship W3023173837A5024070567 @default.
• W3023173837 hasAuthorship W3023173837A5033667607 @default.
• W3023173837 hasAuthorship W3023173837A5042807722 @default.
• W3023173837 hasAuthorship W3023173837A5045002153 @default.
• W3023173837 hasAuthorship W3023173837A5048100872 @default.
• W3023173837 hasAuthorship W3023173837A5049091175 @default.
• W3023173837 hasAuthorship W3023173837A5059278248 @default.
• W3023173837 hasAuthorship W3023173837A5066985276 @default.
• W3023173837 hasAuthorship W3023173837A5071111551 @default.
• W3023173837 hasAuthorship W3023173837A5076785961 @default.
• W3023173837 hasBestOaLocation W30231738371 @default.
• W3023173837 hasConcept C126322002 @default.
• W3023173837 hasConcept C126894567 @default.
• W3023173837 hasConcept C134018914 @default.
• W3023173837 hasConcept C142724271 @default.
• W3023173837 hasConcept C203092338 @default.
• W3023173837 hasConcept C204787440 @default.
• W3023173837 hasConcept C27081682 @default.
• W3023173837 hasConcept C2776297358 @default.
• W3023173837 hasConcept C2777433750 @default.
• W3023173837 hasConcept C2779371878 @default.
• W3023173837 hasConcept C2779609023 @default.
• W3023173837 hasConcept C2781025020 @default.
• W3023173837 hasConcept C2984496839 @default.
• W3023173837 hasConcept C535046627 @default.
• W3023173837 hasConcept C71315377 @default.
• W3023173837 hasConcept C71924100 @default.
• W3023173837 hasConcept C90924648 @default.
• W3023173837 hasConceptScore W3023173837C126322002 @default.
• W3023173837 hasConceptScore W3023173837C126894567 @default.
• W3023173837 hasConceptScore W3023173837C134018914 @default.
• W3023173837 hasConceptScore W3023173837C142724271 @default.
• W3023173837 hasConceptScore W3023173837C203092338 @default.
• W3023173837 hasConceptScore W3023173837C204787440 @default.
• W3023173837 hasConceptScore W3023173837C27081682 @default.
• W3023173837 hasConceptScore W3023173837C2776297358 @default.
• W3023173837 hasConceptScore W3023173837C2777433750 @default.
• W3023173837 hasConceptScore W3023173837C2779371878 @default.
• W3023173837 hasConceptScore W3023173837C2779609023 @default.
• W3023173837 hasConceptScore W3023173837C2781025020 @default.
• W3023173837 hasConceptScore W3023173837C2984496839 @default.
• W3023173837 hasConceptScore W3023173837C535046627 @default.
• W3023173837 hasConceptScore W3023173837C71315377 @default.
• W3023173837 hasConceptScore W3023173837C71924100 @default.
• W3023173837 hasConceptScore W3023173837C90924648 @default.
• W3023173837 hasLocation W30231738371 @default.
• W3023173837 hasOpenAccess W3023173837 @default.
• W3023173837 hasPrimaryLocation W30231738371 @default.
• W3023173837 hasRelatedWork W1033900 @default.
• W3023173837 hasRelatedWork W11097087 @default.
• W3023173837 hasRelatedWork W14685745 @default.
• W3023173837 hasRelatedWork W3556722 @default.
• W3023173837 hasRelatedWork W5794859 @default.
• W3023173837 hasRelatedWork W7686633 @default.
• W3023173837 hasRelatedWork W7911338 @default.
• W3023173837 hasRelatedWork W8376576 @default.
• W3023173837 hasRelatedWork W8820293 @default.
• W3023173837 hasRelatedWork W9705503 @default.
• W3023173837 isParatext "false" @default.
• W3023173837 isRetracted "false" @default.
• W3023173837 magId "3023173837" @default.
• W3023173837 workType "article" @default.